KOREA PACK & ICPI WEEK (Int’l Cosmetic and Pharmaceutical Industry Week) 2022 to Provide O2O Service Connecting Offline Exhibition to the Online Business Platform

5 years ago

GOYANG, South Korea--(BUSINESS WIRE)--#BioPharmaExhibition--KOREA PACK and concurrent event ICPI WEEK (Int’l Cosmetic and Pharmaceutical Industry Week) will be held as…

Confluent and Alibaba Cloud Announce Partnership to set Data in Motion in Mainland China

5 years ago

SINGAPORE--(BUSINESS WIRE)--Confluent, Inc. (NASDAQ: CFLT), the platform for data in motion, and Alibaba Cloud, the digital technology and intelligence backbone…

GLIDE: End of Malaria and Lymphatic Filariasis in Sight for Philippines, Says Award-winning Filipino Doctor

5 years ago

? Dr Fe Esperanza Espino is one of five winners selected to win a Falcon Award for Disease Elimination ?…

Leading Cosmetics Brand Pula Enters the Chinese Market

5 years ago

TOKYO, JAPAN - Media OutReach - 13 December 2021 - Recently, Pula, a well-known Japanese cosmetics brand for children, has enters the…

Understanding the Hehe Culture and A Community of Shared Future for Mankind in Taizhou, Zhejiang

5 years ago

TAIZHOU, China--(BUSINESS WIRE)--Themed “Hehe Culture and A Community of Shared Future for Mankind”, the 2021 Hehe Culture Global Forum was…

BeiGene Presents Results from SEQUOIA Trial of BRUKINSA (zanubrutinib) in First-Line Chronic Lymphocytic Leukemia at the 63rd ASH Annual Meeting

5 years ago

BRUKINSA demonstrated superiority in progression-free survival over chemoimmunotherapy as a first-line treatment for patients with chronic lymphocytic leukemia Consistent efficacy…

Digital Entertainment Leadership Forum’s flagship event on second day

5 years ago

APRU MetaGame Conference focused on education, talent, and the future of esports HONG KONG SAR - Media OutReach - 12…

Valemetostat Pivotal Data Shows Promising Response Rates in Patients with Adult T-Cell Leukemia/Lymphoma

5 years ago

Oral presentation at ASH 2021 features positive phase 2 data in Japanese patients with relapsed/refractory ATL Orphan Drug Designation granted…

BeiGene Presents Updated Safety and Efficacy Findings on BRUKINSA (zanubrutinib) in BTK Inhibitor-Intolerant Patients with Relapsed or Refractory B-Cell Malignancies

5 years ago

Follow-up results from Phase 2 trial suggested intolerable adverse events leading to discontinuation of previous BTK inhibitor therapy were unlikely…

Rare Element Resources Announces Results of Oversubscribed Rights Offering of Common Shares

5 years ago

LITTLETON, Colo.--(BUSINESS WIRE)--Rare Element Resources Ltd. (the “Company” or “RER”) (OTCQB: REEMF) is pleased to report that its previously announced…